Product Description
Mechanisms of Action: CXCL12 Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: NOXXON Pharma AG
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Glioblastoma|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SNOXA12C401 | P2 |
Unknown Status |
Glioblastoma |
2029-12-31 |
|
| GLORIA | P2 |
Active, not recruiting |
Glioblastoma |
2028-12-01 |
|
| OPTIMUS | P2 |
Active, not recruiting |
Pancreatic Cancer |
2025-10-25 |
|
| GLORIA | P2 |
Active, not recruiting |
Glioblastoma |
2022-05-07 |